The discussion shifts to the future of the pharmaceutical industry, focusing on gene editing and CRISPR technology. The hosts argue that services like 23andMe have "normalized" the idea of genetic tracking. They recall past industry discussions about developing vaccines for non-infectious issues, such as cocaine addiction or smoking, as a way to sell medical products to healthy people.